

DRUG PIPELINE

Year after year, one thing remains certain – high-cost therapies are entering the market

In this session we shared that...

- New drugs are becoming available in the costliest therapy classes.
- While the **biosimilars** market is growing, we're still **awaiting the most anticipated releases**.
- More **gene therapies** are coming to market – but at a **premium price**.

... and the only constant we are seeing is change.

- As pharma continues to develop **breakthrough therapies to treat complex conditions**, we will **continue to see unsustainable pricing**
- Drugs losing patent protection in the next 5 years accounts for \$70 million in sales, creating huge potential for savings as generics are developed.

WHAT'S NEXT?

For the latest updates in the drug pipeline, [subscribe to our blog](#).

CONSIDER THIS

Keeping a pulse on new drugs, classes, litigations and patent expirations is critical for the future sustainability of your plan – for your bottom line and your members' health. We have the resources to help, including SafeGuardRx® solutions available for the top four therapy classes driving pharmacy spend. [Explore recent updates](#).